Cryo Adoption Opportunity to engage breast centers and oncology networks to expand adoption of the Visica 2 cryoablation system as a breast-conserving alternative to surgery, emphasizing FDA clearance for fibroadenomas and ongoing FROST study for early stage cancer.

ClinicalStudy Lead Leverage the FROST clinical study involvement to establish thought leadership and create case studies, reimbursement discussions, and physician partnerships that support broader clinical acceptance and patient referrals.

TargetedEducation Develop educational outreach for radiologists and breast surgeons focused on image-guided cryoablation benefits, patient awareness programs, and collaboration with major breast cancer organizations to drive physician and patient adoption.

StrategicPartnerships Identify potential collaborators among mid-size medical centers and regional networks to pilot Visica 2 integration, highlighting minimally invasive approach, quicker recovery, and potential cost savings relative to surgical lumpectomy.

FinancialMomentum Capitalize on the company’s growth trajectory and funding history to secure partnerships or co-development deals with larger medical device players or distributors, while showcasing scalable cloud-based and CRM-enabled sales operations.